DDX53 and cancer: Previous studies have shown that the simultaneous administration of cancer nanovaccines and αPD‐1 further promoted the anti‐tumor efficacy and prolonged MC38‐bearing mouse survival when compared to αPD‐1 alone or combined antigens in the solution.[1a] The combination Nanovaccine_siTGF‐β1 + Pexidartinib + αPD‐1 indeed strongly controlled the tumor growth and prolonged the survival of MC38‐, CT26‐, and B16F10‐bearing mice, in contrast to the association of pexidartinib and αPD‐1 with the delivery of antigens and adjuvants in solution.